Cerenome (PSTV) Non Operating Income (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Non Operating Income of $173000.0 for Q1 2026, up 101.25% year-over-year from $85963.7 in Q1 2025, and up 496.55% quarter-over-quarter from $29000.0 in Q4 2025.
Cerenome (PSTV) Non Operating Income (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Non Operating Income for 16 consecutive years, with $173000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 101.25% year-over-year to $173000.0; the TTM figure through Mar 2026 stood at $7.0 million (up 157.03% YoY), while the FY2025 annual figure was -$7.1 million, down 512.81% from the prior year.
- Non Operating Income climbed to $173000.0 in Q1 2026 per PSTV's latest filing, from $29000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $6.7 million in Q2 2025 and bottomed at -$13.9 million in Q1 2025.
- Historically, Non Operating Income has averaged -$338588.2 across 5 years, with a median of $29000.0 in 2025.
- Annual changes were most pronounced in 2024 — Non Operating Income jumped 9362.5% — and 2025, when it plunged 36586.84%.
- Plus Therapeutics' Non Operating Income stood at -$86000.0 in 2022, then jumped by 155.81% to $48000.0 in 2023, then slumped by 106.25% to -$3000.0 in 2024, then soared by 1066.67% to $29000.0 in 2025, then soared by 496.55% to $173000.0 in 2026.
- Business Quant data shows PSTV's Non Operating Income at $173000.0 in Q1 2026, $29000.0 in Q4 2025, and $59000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 51,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 173,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 6.69 Mn |
| Mar 31, 2025 | -13.87 Mn |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | 925,000.00 |
| Jun 30, 2024 | 757,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -83,000.00 |
| Dec 31, 2022 | -86,000.00 |
| Sep 30, 2022 | -125,000.00 |
| Jun 30, 2022 | -162,000.00 |
| Mar 31, 2022 | -190,000.00 |
| Dec 31, 2021 | -216,000.00 |
| Sep 30, 2021 | -225,000.00 |
| Jun 30, 2021 | -225,000.00 |